| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 105.6 | 84.1 | 72.7 |
| Other income | 1.1 | 1.0 | 1.0 |
| Total income | 106.7 | 85.1 | 73.8 |
| Profit before exceptional items & tax | 9.5 | 8.3 | 5.1 |
| Profit before tax | 9.5 | 8.3 | 5.1 |
| Net profit | 6.5 | 5.6 | 3.7 |
| Operating margin | 8.9% | 9.8% | 6.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +75.70% |
|---|---|
| Net profit, quarter on quarter | +16.10% |
| Revenue, year on year | +45.30% |
NSE results filing, NSE: INFINIUM. Figures extracted from the filing.
Infinium Pharmachem Ltd: key numbers
- Share price
- ₹307.35
- Market cap
- ₹427.7 Cr
- Revenue (annual)
- ₹189.6 Cr
- Net profit (annual)
- ₹12.15 Cr
- P/E (TTM)
- 35.2×Sector 47.4×
- Promoter holding
- 64.91%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Infinium Pharmachem Ltd
All →Infinium Pharmachem Credit Rating
ICRA assigned a new [ICRA]BBB (Stable) rating to Infinium Pharmachem's ₹52.20 Crore credit facilities. The assignment covers cash credit, term loans, and unallocated limits from ICICI Bank and SBI.
Infinium Pharmachem Annual General Meeting
Infinium Pharmachem Limited held its 22nd Annual General Meeting on September 17, 2026. Shareholders transacted ordinary and special business, including director appointments and remuneration revisions.
Infinium Pharmachem SME to Main Board Migration
Infinium Pharmachem Limited issued a postal ballot notice to seek shareholder approval for migrating its equity shares from the NSE Emerge platform to the main board.
Infinium Pharmachem Annual General Meeting
Infinium Pharmachem Limited issued a notice for its Annual General Meeting to be held on September 17, 2026. The meeting agenda includes financial statement adoption and director re-appointments.
Infinium Pharmachem Management Change
Infinium Pharmachem Limited has appointed M/s. Ronak R Jain & Associates as Internal Auditor and M/s. RTBR & Associates as Secretarial Auditor. The company also re-appointed BRS & Associates as Cost Auditor.
Infinium Pharmachem Other Announcement
Infinium Pharmachem Limited has appointed an Internal Auditor, Secretarial Auditor, and Cost Auditor for the Financial Year 2026-27 to comply with statutory regulatory requirements.